¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time and motion studies"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • retrograde motion
    ¿ªÇà¿îµ¿
  • uniform circular motion
    µî¼Ó¿ø¿îµ¿
  • anxious and fearful personality
    ºÒ¾È°øÆ÷ÀΰÝ
  • arch and band appliance
    Ȱ¶ìÀåÄ¡
  • bilateral cleft lip and palate
    ¾çÂÊÀÔ¼úÀÔõÀå°¥¸²Áõ, ¾çÃø±¸¼ø±¸°³¿­
  • bread-and-butter pericarditis
    »§¹öÅ͸ð¾ç½ÉÀ帷¿°
  • complementary and alternative medicine
    º¸Ãæ´ë¾ÈÀÇÇÐ, º¸¿Ï´ëüÀÇÇÐ
  • Center for Disease Control and Prevention
    Áúº´°ü¸®¿¹¹æ¼¾ÅÍ
  • dilatation and curettage
    Àڱñܾ(¼ú), ÀÚ±Ã¼ÒÆÄ(¼ú)
  • foot-and-mouth disease
    ÀԹߺ´, ±¸Á¦¿ª
  • half and half nail
    ¹Ý°ú¹Ý¼Õ¹ßÅé
  • incision and drainage
    1. Àý°³¹è³ó(¼ú) 2. Àý°³¹è¾×(¼ú)
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • kidney ureter and bladder
    ÄáÆÏ¿ä°ü¹æ±¤´Ü¼øÃÔ¿µ
  • law of weights and measures
    °è·®¹ý
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Æø·Î½Ã°£
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • inspiratory pause time
    µé¼ûÈĽ¬´Â½Ã°£, Èí±âÈÄÈÞÁö½Ã°£
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
  • latent time
    Àẹ½Ã°£
  • maximum phonation time
    ÃÖÀå¹ß¼ºÁö¼Ó½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • reaction time
    ¹ÝÀÀ½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • repetition time
    ¹Ýº¹½Ã°£
  • scrub time
    ¼Õ¾Ä´Â½Ã°£
  • survival time
    »ýÁ¸±â°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • motion sickness
    ¸Ö¹Ì
  • motion artifact suppression technique
    ¿îµ¿ÀΰøÀ½¿µ¾ïÁ¦¼ú
  • perpetual motion
    ¿µ±¸¿îµ¿
  • relative motion
    »ó´ë¿îµ¿
  • rephasing gradient motion
    ÀçÀ§»ó°æ»ç¿îµ¿
  • retrograde motion
    ¿ªÇà¿îµ¿
  • sector scan motion
    ºÎä²Ã½ºÄµ¿îµ¿
  • uniform circular motion
    µî¼Ó¿ø¿îµ¿
  • vermicular motion
    ²ÞƲ¿îµ¿, ¹ú·¹¿îµ¿
  • anxious and fearful personality
    ºÒ¾È°øÆ÷ÀΰÝ
  • arch and band appliance
    Ȱ¶ìÀåÄ¡
  • split pin and tube attachment
    À¯ÃʺÐÇÒÇÕÁ¤
  • babbling and lalling stage
    ¿Ë¾ËÀ̽ñâ
  • bilateral cleft lip and palate
    ¾çÂÊÀÔ¼úÀÔõÀå°¥¸²Áõ
  • bread and butter pericarditis
    »§¹öÅ͸ð¾ç½ÉÀ帷¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Death and dying
    »ç¸Á°úÀÓÁ¾
  • ENT =ear, nose and throat
    À̺ñÀÎÈİú(ÇÐ)
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • Gravity, cardiac output and
    Áß·Â(ñìÕô), ½É¹ÚÃâ·®(ãýÚÑõóÕá)
  • KUB= kidney, ureter and bladder
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • PACS (picture archiving and communicating system)
    ÆÑ½º, ¿µ»ó ÀúÀå ¹× Àü¼Û ü°è
  • PANSS=Positive and Negative Syndrome Scale
    ¾ç¼º À½¼º ÁõÈıº ôµµ
  • SADS, Schedule for Affective Disorders and Schizophrenia
    Á¤µ¿Àå¾Ö¿Í Á¤½ÅºÐ¿­º´ÀÇ Áø´ÜÀ» À§ÇÑ ¸ñ·Ï
  • SOFAS, Social and Occupational Functioning Assessment Scale
    »çȸ-Á÷¾÷±â´ÉÆò°¡Ã´µµ
  • SONAR(Sound Navigation and Ranging)
    ¼Ò³ª
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • alternate hot and cold caloric examination
    ³Ã¿Â±³´ë(¿Âµµ)Àڱذ˻ç(ÕÒè®Îßû»è®öôô§Ð½ËþÞÛ).
  • ambient temperature and pressure saturated with water vapor =ATP
    ½Ç¿Â´ë±â¾Ð ¼öÁõ±â Æ÷È­»óÅÂ
  • american society of therapeutic radiology and onco
    logy (ASTRO) ¹Ì±¹¹æ»ç¼±Á¾¾çÇÐȸ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hand motion
    ¼ÕÈçµë, ¾ÈÀü¼öµ¿
  • intravoxel coherent motion (IVCM) imaging
    º¹¼¿³» °áÁý ¿îµ¿ ¿µ»ó
  • intravoxel incoherent motion (IVIM) imaging
    º¹¼¿³» ºñ°áÁý ¿îµ¿ ¿µ»ó
  • intravoxel motion
    º¹¼¿³» ¿îµ¿
  • kinetosis =motion sickness
    µ¿¿äº´(ÔÑèô Ü»), ¿îµ¿º´(¡­Ü»)
  • linear scan motion
    ¼±Çü (àÊû¡) ½ºÄµ ¿îµ¿ (ê¡ÔÑ)
  • linear scan motion
    ¼±Çü ½ºÄµ ¿îµ¿
  • molecular motion
    ºÐÀڿ(¡­ê¡ÔÑ).
  • motion
    ¿îµ¿
  • motion artifact
    ¿îµ¿ Àΰø¹°
  • motion artifact suppression technique
    ¿îµ¿ Àΰø À½¿µ ¾ïÁ¦¼ú
  • motion compensation gradient
    ¿îµ¿ º¸»ó °æ»ç
  • motion parallax
    ¿ø±Ù½ÃÂ÷(êÀÐÎãÊó¬).
  • motion parallax
    ¿îµ¿½ÃÂ÷, ¿îµ¿ÆÄ¶ó¶ô½º
  • motion perception
    ¿îµ¿ÀνÄ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Mesenteries and peritoneal folds
    âÀÚ°£¸· ¹× º¹¸·ÁÖ¸§
    [¿¾ ¿ë¾î] Àå°£¸·
  • Coeloms and septa
    ü°­°ú Áß°Ý
    [¿¾ ¿ë¾î] ü°­°ú Áß°Ý
  • Gray matter (Nuclei and Columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
    [¿¾ ¿ë¾î] ȸ¹éÁú
  • Cartilages and Articulations of Larynx
    Èĵο¬°ñ ¹× ÈĵΰüÀý
    [¿¾ ¿ë¾î] Èĵο¬°ñ ¹× ÈĵΰüÀý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • assimilation time
    µ¿È­ÀÛ¿ë ½Ã°£ (ÔÒûùíÂéÄãÁÊà)
  • clotting time
    ÀÀ°í½Ã°£(ëêͳãÁÊà)
  • coincidence time
    µ¿½Ã½Ã°£(ÔÒãÁãÁÊà)
  • double beam in time spectrophotometer
    ½Ö±¤¼Ó ½Ã°£ ºÐ±¤±¤µµ°è(äªÎÃãÁÊàáÜÝÂÎÃÎÃÓøÍª)
  • elution time
    ¿ë¸® ½Ã°£ (éÁ×îãÁÊà)
  • fixed time assay
    ÀÏÁ¤½Ã°£(ìéïÒãÁÊà) ¾Æ½êÀÌ
  • generation time
    ¼¼´ë ½Ã°£(á¦ÓÛãÁÊà)
  • generation-time hypothesis
    ¼¼´ë ½Ã°£ ¼³(á¦ÓÛãÁÊààã)
  • half-reaction time
    ¹Ý¹ÝÀÀ ½Ã°£(ÚâÚãëëãÁÊà)
  • half-time
    ¹Ý ½Ã°£(ÚâãÁÊà)
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • mean generation time
    Æò±Õ¼¼´ë±â°£(øÁгá¦ÓáÑ¢Êà)
  • recovery time
    ȸ¼ö ½Ã°£(üÞâ¥ãÁÊà)
  • relaxation time
    ÀÌ¿Ï ½Ã°£(ì¬èÐãÁÊà)
  • residence time
    µ¿°Å ½Ã°£(ÔÒËÜãÁÊà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bulk motion
    µ¢¾î¸®¿îµ¿
  • compound scan motion
    º¹ÇÕ½ºÄµ¿îµ¿
  • gradient motion rephasing [=GMR]
    °æ»ç¿îµ¿ÀçÀ§»ó
  • intravoxel coherent motion [=IVCM] imaging
    º¹¼¿³»°áÁý¿îµ¿¿µ»ó
  • intravoxel incoherent motion [=IVIM] imaging
    º¹¼¿³»ºñ°áÁý¿îµ¿¿µ»ó
  • intravoxel motion
    º¹¼¿³»¿îµ¿
  • linear scan motion
    ¼±Çü½ºÄµ¿îµ¿
  • motion
    ¿îµ¿, ¹èº¯
  • motion artifact
    ¿îµ¿Àΰø¹°
  • motion artifact suppression technique
    ¿îµ¿ÀΰøÀ½¿µ¾ïÁ¦¼ú
  • motion compensation gradient
    ¿îµ¿º¸»ó°æ»ç
  • nonuniform motion
    ºñ±ÕÀϿ
  • range of motion
    ¿îµ¿¹üÀ§, ¿îµ¿ÇѰè
  • rephasing gradient motion
    ÀçÀ§»ó°æ»ç¿îµ¿
  • sector scan motion
    ºÎä²Ã½ºÄµ¿îµ¿
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AAROM active assertive range of motion; active-assisted range of motion
AMR acoustic muscle reflex; activity metabolic rate; acute mitral stenosis; alopecia-mental retardation ...
LOM left otitis media; limitation of motion; loss of motion
PROM passive range of motion; premature rupture of fetal membranes; prolonged rupture of fetal membranes;...
SAM S-adenosyl-L-methionine; scanning acoustic microscope; senescence accelerated mouse; sex arousal mec...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EPS Electrophysiological studies
EPESE Established Population for Epidemiologic Studies of the Elderly
NCS Nerve Conduction Studies
SOLVD Studies Of Left Ventricular Dysfunction
35S Studies of
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • object motion
    ÇÇ»çü µ¿¿ä
  • passive range of motion
    ¼öµ¿Àû ¿îµ¿ ¹üÀ§
    ´Ù¸¥ »ç¶÷À̳ª ±â°è ¶Ç´Â ¿ÜºÎÀÇ Èû¿¡ ÀÇÇÏ¿© ±³ÇÕ, °ü·Ã °üÀý³¶, Àδë, ±ÙÀ°À¸·Î Àü´ÞµÈ ¿îµ¿.
  • range of motion
    ¿îµ¿ ¹üÀ§, ¿îµ¿ ÇѰè
    °üÀýÀÌ Æî ¼ö ÀÖ´Â ¿øÀÇ °¢µµ¸¦ ÃøÁ¤ÇÑ ¹üÀ§·Î¼­ ÀϹÝÀûÀ¸·Î ÃøµÎÇϾǰüÀý¿¡¼­´Â °¢µµº¸´Ù´Â ÀýÄ¡ °£ ÇÏ¾Ç È°ÁÖ¸¦ ¹Ì¸®¹ÌÅÍ·Î º¸°íÇÑ´Ù.
  • range-of motion exercise
    ¿îµ¿ ¹üÀ§ ³» ¿îµ¿ ¿ä¹ý
  • spin echo intravoxel incoherent motion imaging
    ½ºÇÉ ¿¡ÄÚÈ­ Àû¼Ò³» ºñ°áÁý ¿îµ¿ ¿µ»ó¼ú
  • uniform : ´Ù¾çÇÔ, ÇüÅ¿¡ À־ÀÇ º¯È­, ¸ðµç ¹ß»ý ¶Ç´Â ¡ÈÄ¿¡ À־ÀÇ Æ¯Â¡ÀÌ ºÎÁ·ÇÑ »óÅÂ.

    uniform circular motion

    µî¼Ó ¿ø¿îµ¿
  • acquisition time
    ȹµæ ½Ã°£
  • activated coagulation time
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • area under the concentration-time curve
    Ç÷Áß ³óµµ °î¼±ÇÏ ¸éÀû, Ç÷Áß ¾à¹° ³óµµ °î¼±ÇÏ ¸éÀû
  • arm to lung time test
    ÆÈ Æó ¼øÈ¯ ½Ã°£ ½ÃÇè
  • arm-to-retina circulation time
    ÆÈ ¸Á¸· ¼øÈ¯ ½Ã°£
  • bleeding time test
    ÃâÇ÷ ½Ã°£ ½ÃÇè
  • chair time
    Áø·á ½Ã°£, Ä¡·á ½Ã°£
    ȯÀÚ°¡ Áø´Ü ¹× Ä¡·á ¹Þ±â À§ÇÑ ½Ã°£.
  • change over time
    ½Ã°£¿¡ µû¸¥ º¯È­
  • coagulation time
    ÀÀ°í ½Ã°£
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
pharmalogical studies <pharmacology> Studies to assess the potential harmful or other effects of drugs
(16 Dec 1997)
clinical studies <pharmacology> Human studies that are designed to measure the safety, efficacy, and appropriate dosage of a new drug or biological. Clinical studies routinely involve the use of a placebo group that is given an inactive substance that looks like the test product.
(14 Nov 1997)
cohort studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesised to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
(12 Dec 1998)
combination studies <pharmacology> Studies in which a new drug is evaluated in combination with existing drugs.
(09 Jan 1998)
multicenter studies Controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children.
(12 Dec 1998)
multivariate studies The use of statistical techniques for the simultaneous investigations of the influence of several variables.
(05 Mar 2000)
preclinical studies <pharmacology> Studies in which a drug is tested on animals and in other non-human test systems. Safety information from such studies are used to support an investigational new drug application.
(14 Nov 1997)
sampling studies Studies in which a number of subjects are selected from all subjects in a defined population. Conclusions based on sample results may be attributed only to the population sampled.
(12 Dec 1998)
prospective studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
(12 Dec 1998)
his bundle studies <cardiology> This test studies the electrical activity of the bundle of HIS.
The bundle of HIS is a group of electrical fibres in the heart that are responsible for transmitting the electrical impulses which generate a normal cardiac contraction. This test may be performed in cases of cardiac arrhythmias, to locate a specific area responsible for a conduction defect and to determine the need for cardiac pacemaker placement.
The test involves the passage of a an electrode tipped catheter into the heart. This catheter is usually threaded through a neck, arm or chest vein. Measurements of the HIS bundle can then be performed while standard ECG leads are placed on the arms and legs.
This test carries a small risk of bleeding, arrhythmias, embolism, heart attack and stroke. It is performed by a specially trained cardiologist.
(27 Sep 1997)
immunofluorescent studies <technique> A special assay that relies on the production of measurable fluorescent light. An immunofluorescent tagged antibody interacts and binds with an antigen allowing an indirect measurement of its concentration.
(27 Sep 1997)
intervention studies Epidemiologic investigations designed to test a hypothesised cause-effect relation by modifying the supposed causal factor(s) in the study population.
(12 Dec 1998)
intracardiac electrophysiology studies <cardiology, investigation> A special study that involves the placement of electrodes inside the heart to map the electrical characteristics of the heart.
This study is carried out in a specially equipped lab and is similar to a cardiac catheterisation procedure. Electrodes are placed inside the heart via a catheter placed into a vein. The electrodes are positioned near the heart's conduction system and an electrical map of the heart can be determined.
This test is often performed in those where a life-threatening cardiac arrhythmia is a problem. The location and characteristics of an arrhythmia can be determined, thus guiding medical management of the problem. Patients with Wolf Parkinson White syndrome or sick sinus syndrome may have this test as part of their evaluation.
(27 Sep 1997)
organizational case studies Descriptions and evaluations of specific health care organizations.
(12 Dec 1998)
electrophysiological studies <investigation> A special study that involves the placement of electrodes inside the heart to map the electrical characteristics of the heart.
This study is carried out in a specially equipped lab and is similar to a cardiac catheterisation procedure. Electrodes are placed inside the heart via a catheter placed into a vein. The electrodes are positioned near the heart's conduction system and an electrical map of the heart can be determined. This test is often performed in those where a life-threatening cardiac arrhythmia is a problem.
The location and characteristics of an arrhythmia can be determined, thus guiding medical management of the problem. Patients with Wolf Parkinson White syndrome or sick sinus syndrome may have this test as part of their evaluation.
Acronym: EPS
(14 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • and not ~ either
    ¶Ç ~ ¾Æ´Ï´Ù(=nor)
  • and so forth
    ±âŸ µîµî
  • and so on
    ..µîµî
  • and such
    µûÀ§,µîµî
  • and that
    ±×°Íµµ,°Ô´Ù°¡
  • both ~ and -
    ~ µµ - µµ (µÑ´Ù)
  • by and by
    ÀÌÀ¹°í
  • by-and-by
    ¹Ì·¡
  • checks and balances
    °ßÁ¦¿Í ±ÕÇü
  • every now and then
    À̵û±Ý
  • here and there
    ¿©±âÀú±â¿¡
  • hide-and-go-seek
    ¼û¹Ù²ÀÁú
  • hide-and-seek
    ¼û¹Ù²ÀÁú
  • hole-and-corner
    ºñ¹ÐÀÇ
  • kith and kin
    ģôÁö±â, Àϰ¡Ä£Ã´
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á